E
CDAK

Ergoteles’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Ergoteles’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-38,019
Closed -$30K – 2081
2022
Q3 		$30K Sell
38,019
-34,960
-48% -$73.4K ﹤0.01% 1466
2022
Q2 		$210K Buy
+72,979
New +$256K 0.01% 1300

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ergoteles's CDAK Position: Q4 2022 in Review

Ergoteles sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2022, closing a stake of 38,019 shares — an estimated $30K sold.

Ergoteles first reported a position in CDAK in Q2 2022 and held it in 2 quarters. The position peaked at $210K in Q2 2022. 40 funds tracked by Wall St. Rank hold CDAK as of Q4 2022.

  • Ergoteles reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 38,019 Codiak BioSciences, Inc. Common Stock shares in Q4 2022, an estimated $30K.
  • Ergoteles first reported a position in Codiak BioSciences, Inc. Common Stock in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Codiak BioSciences, Inc. Common Stock position peaked at $210K in Q2 2022.
  • 40 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.